Structure Therapeutics Files 8-K on Financials
Ticker: GPCR · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1888886
| Field | Detail |
|---|---|
| Company | Structure Therapeutics Inc. (GPCR) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Structure Therapeutics dropped an 8-K on financials, formerly ShouTi Inc.
AI Summary
Structure Therapeutics Inc. filed an 8-K on March 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as ShouTi Inc. and changed its name on October 19, 2021.
Why It Matters
This 8-K filing provides an update on Structure Therapeutics' financial condition and operations, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Structure Therapeutics Inc. (company) — Registrant
- March 8, 2024 (date) — Date of Report
- ShouTi Inc. (company) — Former Company Name
- October 19, 2021 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Structure Therapeutics Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 8, 2024.
What was Structure Therapeutics Inc. formerly known as?
Structure Therapeutics Inc. was formerly known as ShouTi Inc.
When did the company change its name from ShouTi Inc. to Structure Therapeutics Inc.?
The company changed its name from ShouTi Inc. on October 19, 2021.
In which jurisdiction is Structure Therapeutics Inc. incorporated?
Structure Therapeutics Inc. is incorporated in the Cayman Islands.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-08 08:43:20
Key Financial Figures
- $0.0001 — enting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glob
Filing Documents
- tm248154d1_8k.htm (8-K) — 33KB
- tm248154d1_ex99-1.htm (EX-99.1) — 52KB
- tm248154d1_ex99-1img01.jpg (GRAPHIC) — 6KB
- 0001104659-24-032121.txt ( ) — 322KB
- gpcr-20240308.xsd (EX-101.SCH) — 4KB
- gpcr-20240308_def.xml (EX-101.DEF) — 27KB
- gpcr-20240308_lab.xml (EX-101.LAB) — 36KB
- gpcr-20240308_pre.xml (EX-101.PRE) — 25KB
- tm248154d1_8k_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 8, 2024, Structure Therapeutics Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Structure Therapeutics Inc. Date:March 8, 2024 By: /s/ Raymond Stevens Raymond Stevens, Ph.D. Chief Executive Officer